Takeda Announces Exclusive License and Option Agreement with Natrogen for Development of Natura-alpha for Inflammatory Bowel Disease

Takeda Pharmaceutical Company Limited TKPYY and Natrogen Therapeutics International, Inc. (“Natrogen”) jointly announced today an agreement whereby Takeda will acquire an exclusive license to develop Natrogen's Natura-alpha compound as well as an option to acquire Natrogen. Natura-alpha is a synthetic small molecule oral compound that is believed to inhibit pro-inflammatory cytokine expression, which may help to reduce gastrointestinal inflammation. Natura-alpha is currently in Phase 2 development for the treatment of ulcerative colitis (UC). “Today's announcement reinforces Takeda's continued commitment toward addressing the needs of patients with gastrointestinal diseases,” said Asit Parikh, M.D., Ph.D., vice president, general medicine, Takeda. “Natura-alpha is a strategic fit with our gastrointestinal portfolio, See full press release